Form 4: Intellia Therapeutics EVP Laura Sepp-Lorenzino Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, sold shares to cover tax obligations arising from vesting RSUs.
Summary
- On January 3, 2025, Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, sold 8,966 shares of common stock at a price of $12.18 per share.
- The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
- Following the transaction, Sepp-Lorenzino beneficially owns 77,388 shares of Intellia Therapeutics stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | RSUs vested, triggering tax obligations. |
| 01/03/2025 | Sale of 8,966 shares of NTLA common stock. |
| 01/07/2025 | Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.